Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — Investor Presentation (January 2023)
21 slides from Alaunos Therapeutics's investor presentation, Jan 9, 2023
Slide 1: Attacking Solid Tumors with Novel TCR-T Cell Therapies
Exhibit 99.1 Attacking Solid Tumors with Novel TCR-T Cell Therapies January 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will
Slide 3: Delivering the Promise: Leading the Fight Against Solid Tumors with TCR-T
Delivering the Promise: Leading the Fight Against Solid Tumors with TCR-T 2022 2023 2024+ Significant Accomplishments Anticipated Milestones Building for the Future First TCR-T objective clinical Phase 2 readiness Pivotal clinical trials response in solid tumors Expand TCR library to 15 Combination
Slide 4: Comprehensive TCR-T Platform with Multiple Solid Tumor Programs in Pipeline
Comprehensive TCR-T Platform with Multiple Solid Tumor Programs in Pipeline PROGRAM TARGETS INDICATION PRECLINICAL IND-ENABLING PHASE 1 PHASE 2 Lung KRAS G12D & G12V Colon/Rectum TP53 Endometrium Library TCR-T Cell R175H, R248W, Therapy Pancreas R273C & Y220C Ovary EGFR E746-A750del Bile Duct mbIL-1
Slide 5: Hotspot Mutations are Ideal Targets for TCR-T Cells to Treat Solid Tumors
Hotspot Mutations are Ideal Targets for TCR-T Cells to Treat Solid Tumors Target Examples Key Advantages Key Disadvantages • Drives cancer • Highly expressed targets • Hotspot Mutations Mutated EGFR, KRAS or TP53 Single targets • Not on normal tissue • Large addressable market • Small addressable ma
Slide 6: KRAS, TP53, EGFR Mutations are Commonly Expressed in Targeted Solid Tumor Indications
KRAS, TP53, EGFR Mutations are Commonly Expressed in Targeted Solid Tumor Indications Nearly 2 million solid tumors cases diagnosed in United States annually High frequency tumor targets, not expressed in normal tissues These six indications represent ~600,000 new cases per year 6 Source: Most recen
Slide 7: Confirmed Responses from Leading Academic Institutions Corroborate Targeting Hotspot Mutations
Confirmed Responses from Leading Academic Institutions Corroborate Targeting Hotspot Mutations with TCR-T Cells Greater than 70% tumor reduction of metastatic 55% tumor reduction of metastatic breast cancer six months after infusion of TP53-R175H and HLA-A*02:01 pancreatic cancer six months after in
Slide 8: Differentiated Approach to Convert Natural T-Cell Responses into TCR-T Cell Therapy
Differentiated Approach to Convert Natural T-Cell Responses into TCR-T Cell Therapy for a Broad Patient Population TCR Source TCR Library Manufacture TCR-T Cell Therapy Natural TIL 1. Isolate Reactive Autologous TCR-T Response to TCR to Target A Cells Reactive to Target A Target A 2. Make Sleeping B
Slide 9: Unparalleled TCR Library Captures Both High Frequency Mutations and HLA Types
Unparalleled TCR Library Captures Both High Frequency Mutations and HLA Types Recently added TCRs via IND amendment: KRAS-G12V and DRB1*07:01 TP53-R273C and DPB1*04:02 Our TCR library contains mutations from genes that are known to drive cancer and are highly expressed by tumors Mutations in our lib
Slide 10: Non-viral Sleeping Beauty Platform Well Suited for Manufacturing TCR-T Cells
Non-viral Sleeping Beauty Platform Well Suited for Manufacturing TCR-T Cells without Complexity of Gene Editing • Efficient, essentially random integration without complexity of gene editing or viral approaches • Rapid, cost-effective manufacturing • Flexible approach to add TCRs; attractive choice
Slide 11: TCR-T Cells Recognize KRAS, TP53, EGFR Mutations and Kill Solid Tumor Cells
TCR-T Cells Recognize KRAS, TP53, EGFR Mutations and Kill Solid Tumor Cells Powerful TCRs: Naturally-occurring, high avidity TCRs recognize low levels of neoantigens No off-target toxicity observed: Specificity for the mutation with negligible recognition of wild type sequences Tumor killing: Recogn
Slide 12: TCR-T Cell Products are Manufactured with a TCR Matched to Each Patient's Tumor Mutation
TCR-T Cell Products are Manufactured with a TCR Matched to Each Patient’s Tumor Mutation and HLA Type Screening 1 2 Selection of TCR from Infusion 7 Library for Manufacturing Formulate & 3 6 Cryopreserve Peripheral Blood Leukapheresis Sleeping Beauty 5 4 Transposition of TCR TCR Expression & Expansi
Slide 13: Universal, In-House Manufacturing Platform Delivers High Quality TCR-T Cell Products
Universal, In-House Manufacturing Platform Delivers High Quality TCR-T Cell Products Ongoing Process Optimization Patient 1 Patient 2 Patient 3 Mutation KRAS-G12D TP53-R175H KRAS-G12V Automation and closed process steps to increase throughput Indication Lung Colorectal Pancreatic Dose Level One Two
Slide 14: First-in-Human TCR-T Clinical Trial Actively Enrolling with Innovative Library Approach
First-in-Human TCR-T Clinical Trial Actively Enrolling with Innovative Library Approach • Defines safety and dose with any TCR and any indication Phase 1 • Enrolling in one of three dose cohorts: 5, 40 and 100 billion TCR-T cells • Defines efficacy at recommended dose with any TCR in library Phase 2
Slide 15: First-in-Human Confirmed Response in Solid Tumors by Sleeping Beauty TCR-T Cell Therapy
First-in-Human Confirmed Response in Solid Tumors by Sleeping Beauty TCR-T Cell Therapy SAFETY PERSISTENCE EFFICACY Manageable safety profiles Persisting TCR-T cells First TCR-T cell response in in first two dose levels (20%-30%) in blood checkpoint inhibitor refractory NSCLC No DLTs TCR-T cells tra
Slide 16: Patient Showed Durable, Complete Resolution of NSCLC Lesion Through Six Months
Patient 1 Showed Durable, Complete Resolution of NSCLC Lesion Through Six Months Insert Image Here Insert Image Here Insert Image Here 24 0 6 12 Baseline Week 6 Week 12 Week 24 • Patient 1 had multiple lines of prior therapy and was refractory to checkpoint inhibitors • Treated with 9 billion TCR-T
Slide 17: TCR-T Cells Persist in Blood and Traffic to Tumor Microenvironment
TCR-T Cells Persist in Blood and Traffic to Tumor Microenvironment Mutation and HLA were present in post-treatment tumors Patient 1: TCR-T Cell Persistence in Blood Six-month Tumor Biopsy 1 0 0 Patient 1 Patient 2 8 0 TCR-T 6.1% 6 0 TCR-T cells were detected in peripheral blood at last follow-up 4 0
Slide 18: Next Generation TCR-T Efforts Aim to Deepen Clinical Responses
Next Generation TCR-T Efforts Aim to Deepen Clinical Responses Augmenting TCR-T Survival Combine TCR-T and Immune Multiple TCRs infused into Checkpoint Inhibitors the Same Patient via Co-Expression of mbIL-15 Regeneration of effector Reinvigorate TCR-T cells in the Attack multiple targets on the tum
Slide 19: hunTR Potentially Expands TCR Library, Increases Addressable Market
® hunTR Potentially Expands TCR Library, Increases Addressable Market and Enables Multiplexed TCR-T Cell Therapy Add new HLAs to existing mutations and add 2024+ more key mutations within EGFR, KRAS, TP53 40+ TCRs 2023 Matching data from clinical efforts inform which 15 HLA/mutation combinations to
Slide 20: Experienced Management Team
Experienced Management Team Melinda Lackey Kevin S. Boyle, Sr. SVP Legal Chief Executive Officer Drew Deniger, PhD Abhishek Srivastava, PhD Mike Wong VP Research & Development VP Technical Operations VP Finance Melinda Lackey 20
Slide 21: 2023 Milestones Designed to Retain Our Leadership Position in TCR-T Cell Therapy
2023 Milestones Designed to Retain Our Leadership Position in TCR-T Cell Therapy for the Treatment of Solid Tumors Advance TCR-T Optimize New IND for Expand TCR Library trial to manufacturing Library to 15 TCRs mbIL-15 TCR-T Phase 2 process towards commercial Translational scalability assessment-dri
Alaunos Therapeutics — Investor Presentation (January 2023) on 6ix